Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine, as well as AEB4104, an engineered human enzyme that targets the reduction of elevated levels of the amino acid homocysteine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone512-942-2935
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.20 million
Profitability
Miscellaneous
Employees43
OptionableOptionable
Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions
What is Aeglea Bio Therapeutics' stock symbol?
Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE."
How were Aeglea Bio Therapeutics' earnings last quarter?
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) announced its earnings results on Thursday, November, 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.10. Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 62.12%. View Aeglea Bio Therapeutics' Earnings History.
When is Aeglea Bio Therapeutics' next earnings date?
What price target have analysts set for AGLE?
4 equities research analysts have issued twelve-month price targets for Aeglea Bio Therapeutics' shares. Their forecasts range from $20.00 to $37.00. On average, they expect Aeglea Bio Therapeutics' share price to reach $26.00 in the next year. This suggests a possible upside of 197.5% from the stock's current price. View Analyst Price Targets for Aeglea Bio Therapeutics.
What is the consensus analysts' recommendation for Aeglea Bio Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea Bio Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aeglea Bio Therapeutics.
Has Aeglea Bio Therapeutics been receiving favorable news coverage?
Press coverage about AGLE stock has been trending positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aeglea Bio Therapeutics earned a daily sentiment score of 2.8 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the company's share price in the near future.
Who are some of Aeglea Bio Therapeutics' key competitors?
Some companies that are related to Aeglea Bio Therapeutics include Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Athenex (ATNX), Radius Health (RDUS), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), ImmunoGen (IMGN), Epizyme (EPZM), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), G1 Therapeutics (GTHX), AC Immune (ACIU), Urogen Pharma (URGN), Rocket Pharmaceuticals (RCKT) and Intra-Cellular Therapies (ITCI).
Who are Aeglea Bio Therapeutics' key executives?
Aeglea Bio Therapeutics' management team includes the folowing people:
- Dr. Anthony G. Quinn M.B Ch.B., Ph.D., FRCP, Pres, CEO & Director (Age 57)
- Mr. Charles N. York II, CFO & VP (Age 42)
- Dr. Leslie Sloan Ph.D., Sr. VP of Operations
- Mr. Eugene Sackett, VP of HR
- Dr. James E. Wooldridge M.D., Chief Medical Officer (Age 53)
When did Aeglea Bio Therapeutics IPO?
(AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.
Who are Aeglea Bio Therapeutics' major shareholders?
Aeglea Bio Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Comprehensive Portfolio Management LLC (1.21%), Meeder Asset Management Inc. (0.02%) and Bank of Montreal Can (0.01%). Company insiders that own Aeglea Bio Therapeutics stock include Aaron Schuchart, Anthony G Quinn, Bioventures Ltd Novartis, Charles N York II and Orbimed Advisors Llc. View Institutional Ownership Trends for Aeglea Bio Therapeutics.
Which institutional investors are selling Aeglea Bio Therapeutics stock?
AGLE stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Aeglea Bio Therapeutics company stock in the last year include Aaron Schuchart and Bioventures Ltd Novartis. View Insider Buying and Selling for Aeglea Bio Therapeutics.
Which institutional investors are buying Aeglea Bio Therapeutics stock?
AGLE stock was acquired by a variety of institutional investors in the last quarter, including Comprehensive Portfolio Management LLC and Meeder Asset Management Inc.. Company insiders that have bought Aeglea Bio Therapeutics stock in the last two years include Anthony G Quinn, Charles N York II and Orbimed Advisors Llc. View Insider Buying and Selling for Aeglea Bio Therapeutics.
How do I buy shares of Aeglea Bio Therapeutics?
Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aeglea Bio Therapeutics' stock price today?
One share of AGLE stock can currently be purchased for approximately $8.74.
How big of a company is Aeglea Bio Therapeutics?
Aeglea Bio Therapeutics has a market capitalization of $209.41 million and generates $5.20 million in revenue each year. The biotechnology company earns $-27,230,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Aeglea Bio Therapeutics employs 43 workers across the globe.
What is Aeglea Bio Therapeutics' official website?
How can I contact Aeglea Bio Therapeutics?
Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]
MarketBeat Community Rating for Aeglea Bio Therapeutics (NASDAQ AGLE)
MarketBeat's community ratings are surveys of what our community members think about Aeglea Bio Therapeutics and other stocks. Vote "Outperform" if you believe AGLE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGLE will underperform the S&P 500 over the long term. You may vote once every thirty days.
